Considerations for the Use of Long-Acting and Extended-Release Agents During Pregnancy and Lactation.

ABSTRACT: Long-acting agents hold significant promise for treating and preventing common illnesses, including infections. Pharmacokinetic and safety data during pregnancy and lactation are often unavailable for new drugs; these data are vital to facilitate optimal drug use by pregnant and lactating women and women who may conceive. In this commentary, we summarize the circumstances in which pregnant and lactating women are likely to use and benefit from long-acting agents. We focus on long-acting formulations of small molecules (rather than biologics such as monoclonal antibodies) and on several infections of global importance (human immunodeficiency virus, tuberculosis, malaria, and hepatitis C). We discuss pregnancy pharmacokinetic/pharmacodynamic and potential safety and efficacy considerations p

SUBMITTER: Olagunju A 

PROVIDER: S-EPMC10200321 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature